ArticleVaccine2007
A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Virus Shedding and Diarrhea: A Review of Human Norovirus Genogroup II Infection in Gnotobiotic Pigs.Viruses · 2024Review
- Current trends and new approaches for human norovirus replication in cell culture: a literature review.Archives of virology · 2024Review
- Advances in Human Norovirus Vaccine Research.Vaccines · 2021Review
- Article
- Article
- Article
- Human Norovirus: Experimental Models of Infection.Viruses · 2019Review
- Norovirus vaccines: Correlates of protection, challenges and limitations.Human vaccines & immunotherapeutics · 2016Review
- A Gnotobiotic Pig Model for Determining Human Norovirus Inactivation by High-Pressure Processing.Applied and environmental microbiology · 2015Article
- Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein.Virology · 2015Article
- Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs.Journal of virology · 2014Article
- Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.Journal of virology · 2014Article
- Advances in norovirus biology.Cell host & microbe · 2014Review
- The state of norovirus vaccines.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- A neonatal gnotobiotic pig model of human enterovirus 71 infection and associated immune responses.Emerging microbes & infections · 2014Article
- Vaccine against norovirus.Human vaccines & immunotherapeutics · 2014Review
- Epidemiology, prevention, and control of the number one foodborne illness: human norovirus.Infectious disease clinics of North America · 2013Review
- Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age.The Journal of general virology · 2013Article
- Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles.Journal of translational medicine · 2013Article
- Virus-like particles: the new frontier of vaccines for animal viral infections.Veterinary immunology and immunopathology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We inoculated gnotobiotic pigs orally/intranasally with human norovirus GII.4 HS66 strain virus-like particles (VLP) and immunostimulating complexes (ISCOM) or mutant E. coli LT toxin (mLT, R192G) as mucosal adjuvants, then assessed intestinal and systemic antibody and cytokine responses and homologous protection. Both vaccines induced high rates of seroconversion (100%) and coproconversion (75-100%). The VLP+mLT vaccine induced Th1/Th2 serum cytokines and cytokine secreting cells, whereas the VLP+ISCOM vaccine induced Th2 biased responses with significantly elevated IgM, IgA and IgG antibody-secreting cells in intestine. Nevertheless, both vaccines induced increased protection rates against viral shedding and diarrhea (75-100%) compared to controls; however, only 57% of controls shed virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.